ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Herpes zoster,Herpes viral infections,Viral infectious disorders,Infec,N
2,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
3,1,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
3,2,Blast cells,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
3,3,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
3,4,Coma,Coma states,Neurological disorders NEC,Nerv,N
3,5,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
3,6,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
3,7,Hemiparesis,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
3,8,Leukoencephalopathy,Encephalopathies NEC,Encephalopathies,Nerv,Y
3,9,Metastases to central nervous system,Metastases to specified sites,Metastases,Neopl,N
3,10,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
3,11,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
3,12,Speech disorder,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
3,13,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
3,14,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
4,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
4,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
4,3,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
5,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,Y
6,1,Acute abdomen,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
6,2,Biliary tract infection,Hepatobiliary and spleen infections,Infections - pathogen unspecified,Infec,Y
6,3,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
6,4,Peritonitis,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
7,1,Balance disorder,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
7,2,Coma,Coma states,Neurological disorders NEC,Nerv,N
7,3,Death,Death and sudden death,Fatal outcomes,Genrl,Y
7,4,Speech disorder,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
8,1,Circulatory collapse,Circulatory collapse and shock,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
8,2,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
8,3,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
8,4,Herpes zoster,Herpes viral infections,Viral infectious disorders,Infec,N
8,5,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
8,6,Neuralgia,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
9,1,Hepatomegaly,Hepatobiliary signs and symptoms,Hepatic and hepatobiliary disorders,Hepat,N
10,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
11,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
11,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
11,3,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
12,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
12,2,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
12,3,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
13,1,Acute respiratory distress syndrome,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,Y
13,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
13,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
13,4,Lung infiltration,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
13,5,Respiratory failure,Respiratory failures (excl neonatal),Respiratory disorders NEC,Resp,N
13,6,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
14,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
14,2,Drug level increased,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
14,3,Pulmonary hypertension,Pulmonary hypertensions,Pulmonary vascular disorders,Resp,N
15,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
16,1,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
16,2,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
17,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
17,2,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
18,1,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
19,1,Metabolic acidosis,Metabolic acidoses (excl diabetic acidoses),Acid-base disorders,Metab,N
20,1,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
20,2,Cachexia,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
20,3,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
20,4,Death,Death and sudden death,Fatal outcomes,Genrl,Y
20,5,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
20,6,Myeloproliferative neoplasm,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
21,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
22,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
23,1,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
23,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
23,3,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
24,1,Leukaemia,Leukaemias NEC,Leukaemias,Neopl,Y
25,1,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,Y
25,2,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
25,3,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
26,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
27,1,Folliculitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
27,2,Skin infection,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
27,3,Subcutaneous abscess,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
28,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
28,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
29,1,Aspartate aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
29,2,Blood alkaline phosphatase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
29,3,Gamma-glutamyltransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
29,4,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
30,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
30,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
30,3,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
31,1,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
32,1,Inappropriate antidiuretic hormone secretion,Posterior pituitary disorders,Hypothalamus and pituitary gland disorders,Endo,N
33,1,Tuberculosis,Tuberculous infections,Mycobacterial infectious disorders,Infec,N
34,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
34,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
34,3,Full blood count decreased,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
34,4,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
35,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
35,2,Splenic haematoma,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
35,3,Splenic rupture,Abdominal and gastrointestinal injuries NEC,Injuries NEC,Inj&P,N
36,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,Y
37,1,Hyponatraemia,Sodium imbalance,Electrolyte and fluid balance conditions,Metab,N
38,1,Headache,Headaches NEC,Headaches,Nerv,N
38,2,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
38,3,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
39,1,Hyponatraemia,Sodium imbalance,Electrolyte and fluid balance conditions,Metab,N
40,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
40,2,Blast cell count increased,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
40,3,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
41,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
42,1,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,Y
42,2,Retroperitoneal haemorrhage,Peritoneal and retroperitoneal haemorrhages,Peritoneal and retroperitoneal conditions,Gastr,N
43,1,Liver disorder,Hepatic and hepatobiliary disorders NEC,Hepatic and hepatobiliary disorders,Hepat,N
43,2,Spleen disorder,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
43,3,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
44,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
44,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
44,3,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
44,4,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
45,1,Red blood cell count decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
46,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
47,1,Bacterial sepsis,Bacterial infections NEC,Bacterial infectious disorders,Infec,Y
47,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
47,3,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
48,1,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
49,1,Multiple organ dysfunction syndrome,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
49,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
49,3,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
49,4,Septic shock,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
50,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
51,1,Blast cell count increased,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
51,2,Full blood count increased,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
51,3,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
52,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
53,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
54,1,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
55,1,Intestinal perforation,Intestinal ulcers and perforation NEC,Gastrointestinal ulceration and perforation,Gastr,N
55,2,Peritonitis,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,Y
56,1,Renal disorder,Renal disorders NEC,Renal disorders (excl nephropathies),Renal,N
57,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
57,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
57,3,Dry skin,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
57,4,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
57,5,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
57,6,Incoherent,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
57,7,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
57,8,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
57,9,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
57,10,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
57,11,Viral infection,Viral infections NEC,Viral infectious disorders,Infec,N
57,12,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
58,1,Gastrooesophageal reflux disease,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
59,1,Encephalitis herpes,Herpes viral infections,Viral infectious disorders,Infec,Y
59,2,Generalised tonic-clonic seizure,Generalised tonic-clonic seizures,Seizures (incl subtypes),Nerv,N
59,3,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
59,4,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
60,1,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,Y
61,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
61,2,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
61,3,Orthopnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
62,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
62,2,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
62,3,Blast cell count increased,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
62,4,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
62,5,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
62,6,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
63,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
63,2,Splenic infarction,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
63,3,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
64,1,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
65,1,Axonal neuropathy,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
66,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
67,1,Blast cell count increased,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
68,1,Mental disorder,Mental disorders NEC,Psychiatric disorders NEC,Psych,N
69,1,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,Y
69,2,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
69,3,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
69,4,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
70,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
70,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
70,3,Hypoxia,Conditions associated with abnormal gas exchange,Respiratory disorders NEC,Resp,N
70,4,Pneumonia pseudomonal,Pseudomonal infections,Bacterial infectious disorders,Infec,N
70,5,Pulmonary hypertension,Pulmonary hypertensions,Pulmonary vascular disorders,Resp,Y
70,6,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
71,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
71,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
71,3,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
72,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
73,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,Y
73,2,Herpes zoster,Herpes viral infections,Viral infectious disorders,Infec,N
73,3,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
73,4,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
74,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
74,2,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
75,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
75,2,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
76,1,Haemoglobin abnormal,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
76,2,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
76,3,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
77,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
77,2,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
77,3,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
77,4,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
78,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
78,2,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
78,3,Skin ulcer,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
78,4,Thrombocytosis,Thrombocytoses,Platelet disorders,Blood,N
79,1,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
79,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
80,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
80,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
80,3,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
80,4,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
80,5,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
80,6,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
81,1,Bladder neoplasm,Urinary tract neoplasms unspecified malignancy NEC,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
81,2,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
81,3,Dyspnoea exertional,Breathing abnormalities,Respiratory disorders NEC,Resp,N
81,4,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
81,5,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
81,6,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
81,7,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
81,8,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
82,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
82,2,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
82,3,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
82,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
83,1,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
84,1,Adenocarcinoma of colon,Colorectal neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
84,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
84,3,Large intestine perforation,Intestinal ulcers and perforation NEC,Gastrointestinal ulceration and perforation,Gastr,N
84,4,Mouth haemorrhage,Oral soft tissue haemorrhages,Oral soft tissue conditions,Gastr,N
84,5,Post procedural haemorrhage,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
84,6,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
85,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
85,2,Platelet count increased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
85,3,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
85,4,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
86,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
87,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
88,1,Acute febrile neutrophilic dermatosis,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,Y
88,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
88,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
88,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
88,5,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
88,6,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
88,7,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
88,8,Rash pustular,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
88,9,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
88,10,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
88,11,Staphylococcal skin infection,Staphylococcal infections,Bacterial infectious disorders,Infec,N
88,12,Subcutaneous abscess,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
89,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
90,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
90,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
90,3,Leukaemia,Leukaemias NEC,Leukaemias,Neopl,N
90,4,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
90,5,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
91,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
91,2,Haemorrhage subcutaneous,Skin haemorrhages,Skin vascular abnormalities,Skin,N
91,3,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
91,4,Subcutaneous haematoma,Skin injuries NEC,Injuries NEC,Inj&P,N
92,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
92,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
92,3,Femur fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
92,4,Flatulence,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
92,5,Osteoporosis,Metabolic bone disorders,Bone disorders (excl congenital and fractures),Musc,N
93,1,Leukotriene increased,Immunology analyses NEC,Immunology and allergy investigations,Inv,N
94,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
94,2,Aspartate aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
94,3,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
94,4,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
95,1,Agitation,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
95,2,Bacterial infection,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
95,3,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
95,4,Disorientation,Confusion and disorientation,Deliria (incl confusion),Psych,N
95,5,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
95,6,Upper respiratory tract infection,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
96,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
96,2,Gastric ulcer,Gastric ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
97,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
97,2,Demyelination,Demyelinating disorders NEC,Demyelinating disorders,Nerv,N
97,3,Neuromyelitis optica spectrum disorder,Demyelinating disorders NEC,Demyelinating disorders,Nerv,N
97,4,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
98,1,Peripheral sensory neuropathy,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
99,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
100,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
100,2,Drug withdrawal syndrome,Withdrawal and rebound effects,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
100,3,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
100,4,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
101,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
101,2,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
101,3,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
101,4,Demyelination,Demyelinating disorders NEC,Demyelinating disorders,Nerv,N
101,5,Headache,Headaches NEC,Headaches,Nerv,N
101,6,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
101,7,Multiple sclerosis,Multiple sclerosis acute and progressive,Demyelinating disorders,Nerv,N
101,8,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
101,9,Neuromyelitis optica spectrum disorder,Demyelinating disorders NEC,Demyelinating disorders,Nerv,N
101,10,Papilloedema,Optic disc abnormalities NEC,"Ocular structural change, deposit and degeneration NEC",Eye,N
101,11,Visual acuity reduced,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
101,12,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
102,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
102,2,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
102,3,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
102,4,Drug withdrawal syndrome,Withdrawal and rebound effects,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
102,5,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
102,6,Palpitations,Cardiac signs and symptoms NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
102,7,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
102,8,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
102,9,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
102,10,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
102,11,Ventricular tachycardia,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
103,1,Platelet count increased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
104,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
105,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
105,2,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
105,3,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
105,4,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
106,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
107,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
108,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
108,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
108,3,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
108,4,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
109,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
109,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
110,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
111,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
111,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
112,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
112,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
113,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
113,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
113,3,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
113,4,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
114,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
114,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
115,1,Cardiovascular disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
115,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
116,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
117,1,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
118,1,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
119,1,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
120,1,Thrombocytosis,Thrombocytoses,Platelet disorders,Blood,N
121,1,Heart rate increased,Heart rate and pulse investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
121,2,Hyperthermia malignant,Body temperature altered,Body temperature conditions,Genrl,N
122,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
122,2,Blast cell count increased,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
122,3,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
122,4,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
122,5,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
123,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
124,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
125,1,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
126,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
126,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
127,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
127,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
128,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
128,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
129,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
129,2,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
129,3,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
130,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
130,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
130,3,Terminal state,General signs and symptoms NEC,General system disorders NEC,Genrl,N
131,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
132,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
132,2,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
132,3,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
132,4,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
133,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
133,2,Blood erythropoietin increased,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
133,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
133,4,Extramedullary haemopoiesis,Haematological disorders,Haematological disorders NEC,Blood,N
133,5,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
133,6,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
133,7,Pelvic pain,Reproductive tract signs and symptoms NEC,Reproductive tract disorders NEC,Repro,N
133,8,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
133,9,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
133,10,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
134,1,Blood bilirubin increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
134,2,Chromaturia,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
134,3,Faeces discoloured,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
134,4,Hepatomegaly,Hepatobiliary signs and symptoms,Hepatic and hepatobiliary disorders,Hepat,N
134,5,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
134,6,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
134,7,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
135,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
135,2,Night sweats,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
135,3,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
135,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
136,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
136,2,Night sweats,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
136,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
137,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
137,2,Skin infection,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
138,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
139,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
139,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
139,3,Gait disturbance,Gait disturbances,General system disorders NEC,Genrl,N
139,4,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
139,5,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
140,1,Dementia with Lewy bodies,Dementia (excl Alzheimer's type),Mental impairment disorders,Nerv,N
141,1,Neovascular age-related macular degeneration,"Retinal structural change, deposit and degeneration","Ocular structural change, deposit and degeneration NEC",Eye,N
142,1,Blast cell count increased,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
142,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
142,3,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
143,1,Neutrophil count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
143,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
143,3,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
144,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
144,2,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
145,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
145,2,Lymphocyte count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
145,3,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
145,4,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
146,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
147,1,Pancreatitis,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
148,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
148,2,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,Y
148,3,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
148,4,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
149,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
149,2,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
149,3,Blood glucose increased,Carbohydrate tolerance analyses (incl diabetes),"Metabolic, nutritional and blood gas investigations",Inv,N
149,4,Escherichia urinary tract infection,Escherichia infections,Bacterial infectious disorders,Infec,N
149,5,Neutrophil count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
149,6,Pyelonephritis,Urinary tract infections,Infections - pathogen unspecified,Infec,N
150,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
151,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
151,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
151,3,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
152,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
153,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
153,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
153,3,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
153,4,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
154,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
154,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
155,1,Albuminuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
155,2,Hypoglycaemia,Hypoglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
155,3,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
156,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
156,2,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
156,3,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
157,1,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
157,2,Labelled drug-drug interaction medication error,Product monitoring errors and issues,Medication errors and other product use errors and issues,Inj&P,N
158,1,Abdominal pain lower,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
158,2,Bladder pain,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
158,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
159,1,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
160,1,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
160,2,Spleen disorder,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
161,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
161,2,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
162,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
162,2,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
163,1,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
164,1,Blindness unilateral,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
164,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
164,3,Hemiplegia,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
164,4,Nervous system disorder,Nervous system disorders NEC,Neurological disorders NEC,Nerv,N
165,1,Skin cancer,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
166,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
166,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
166,3,Gastrointestinal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
166,4,Haematochezia,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
166,5,Inflammatory bowel disease,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
167,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
167,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
167,3,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
167,4,Spinal cord compression,Spinal cord and nerve root disorders NEC,Spinal cord and nerve root disorders,Nerv,N
167,5,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
167,6,Tuberculosis,Tuberculous infections,Mycobacterial infectious disorders,Infec,N
168,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
168,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
168,3,Exercise tolerance decreased,General signs and symptoms NEC,General system disorders NEC,Genrl,N
168,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
168,5,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
168,6,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
168,7,Myocardial strain imaging,Cardiac function diagnostic procedures,Cardiac and vascular investigations (excl enzyme tests),Inv,N
168,8,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
168,9,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
168,10,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
169,1,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,Y
170,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
171,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
171,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
171,3,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
171,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
171,5,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
171,6,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
171,7,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
172,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
172,2,Lung abscess,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
172,3,Lymphopenia,Leukopenias NEC,White blood cell disorders,Blood,N
172,4,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
172,5,Pulmonary cavitation,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
173,1,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
173,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
173,3,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
173,4,Pulmonary cavitation,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
173,5,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
174,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
175,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
176,1,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
176,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
177,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
177,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
177,3,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
177,4,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
178,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
179,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
180,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
180,2,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
180,3,Chronic graft versus host disease,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
180,4,Congenital aplasia,Congenital disorders NEC,Congenital and hereditary disorders NEC,Cong,N
180,5,Cytomegalovirus infection reactivation,Cytomegaloviral infections,Viral infectious disorders,Infec,N
180,6,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
180,7,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
180,8,Headache,Headaches NEC,Headaches,Nerv,N
180,9,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
180,10,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
180,11,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
180,12,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
180,13,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
181,1,Acute graft versus host disease in skin,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
181,2,Concomitant disease aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
181,3,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
181,4,Early satiety,Feelings and sensations NEC,General system disorders NEC,Genrl,N
181,5,Electrolyte imbalance,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
181,6,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
181,7,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
181,8,Headache,Headaches NEC,Headaches,Nerv,N
181,9,Hepatic encephalopathy,Encephalopathies toxic and metabolic,Encephalopathies,Nerv,N
181,10,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
181,11,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
181,12,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
181,13,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
181,14,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
181,15,Upper gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
181,16,Venoocclusive disease,Non-site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
182,1,Hepatitis E,Hepatitis virus infections,Viral infectious disorders,Infec,N
182,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
183,1,Neuroendocrine carcinoma of the skin,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
184,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
185,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
186,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
186,2,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
187,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
188,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
189,1,Hepatic cancer,Hepatic neoplasms malignant,Hepatobiliary neoplasms malignant and unspecified,Neopl,Y
190,1,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
191,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
191,2,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
192,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
192,2,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
193,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
194,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
195,1,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
196,1,Erythema nodosum,Panniculitides,Skin and subcutaneous tissue disorders NEC,Skin,N
197,1,Myalgia,Muscle pains,Muscle disorders,Musc,N
198,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
199,1,Disseminated tuberculosis,Tuberculous infections,Mycobacterial infectious disorders,Infec,N
199,2,Neck mass,Soft tissue disorders NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
199,3,Night sweats,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
199,4,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
199,5,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
200,1,Factor XI deficiency,Coagulation disorders congenital,Blood and lymphatic system disorders congenital,Cong,N
200,2,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
200,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
201,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
201,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
201,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
202,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
202,2,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,Y
203,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
203,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
204,1,Genital herpes simplex,Herpes viral infections,Viral infectious disorders,Infec,N
204,2,Haematocrit increased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
204,3,Penile ulceration,Skin and subcutaneous tissue ulcerations,Skin and subcutaneous tissue disorders NEC,Skin,N
204,4,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
204,5,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
205,1,Drug withdrawal syndrome,Withdrawal and rebound effects,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
205,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
205,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
206,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
206,2,Bronchopulmonary aspergillosis,Aspergillus infections,Fungal infectious disorders,Infec,Y
207,1,Chronic myeloid leukaemia,Leukaemias chronic myeloid,Leukaemias,Neopl,N
207,2,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
208,1,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
208,2,Skin cancer,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
209,1,Adenocarcinoma,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
209,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
209,3,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
210,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
211,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
211,2,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
212,1,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
212,2,Urosepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
213,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
213,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
214,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
214,2,Diffuse alveolar damage,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
214,3,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
214,4,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
214,5,Myocardial ischaemia,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
215,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
215,2,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
215,3,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
216,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
216,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
216,3,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
216,4,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
217,1,Chronic leukaemia,Leukaemias chronic NEC,Leukaemias,Neopl,N
217,2,Concomitant disease aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
217,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
217,4,Leukaemia recurrent,Leukaemias NEC,Leukaemias,Neopl,N
217,5,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
217,6,Urinary tract disorder,Genital and urinary tract disorders NEC,Genitourinary tract disorders NEC,Renal,N
218,1,Staphylococcal infection,Staphylococcal infections,Bacterial infectious disorders,Infec,N
219,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
219,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
220,1,Ventricular extrasystoles,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
221,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
221,2,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
221,3,Primary myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
222,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
222,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
222,3,Rash vesicular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
223,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
224,1,Herpes zoster,Herpes viral infections,Viral infectious disorders,Infec,N
225,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
225,2,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
225,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
225,4,Night sweats,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
225,5,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
225,6,Withdrawal syndrome,Withdrawal and rebound effects,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
226,1,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
227,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
227,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
227,3,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
228,1,Disturbance in attention,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
228,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
228,3,Dysarthria,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
228,4,Facial paralysis,Facial cranial nerve disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
228,5,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
228,6,Nervous system disorder,Nervous system disorders NEC,Neurological disorders NEC,Nerv,N
228,7,Personality change,Behaviour and socialisation disturbances,Personality disorders and disturbances in behaviour,Psych,N
228,8,Toxic leukoencephalopathy,Encephalopathies toxic and metabolic,Encephalopathies,Nerv,N
229,1,Neoplasm malignant,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
229,2,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
230,1,Deep vein thrombosis,Peripheral embolism and thrombosis,Embolism and thrombosis,Vasc,N
230,2,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
231,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
232,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
233,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
233,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
234,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
234,2,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
234,3,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
234,4,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
235,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
235,2,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
236,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
236,2,Oesophageal carcinoma,Oesophageal neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
237,1,Haematoma,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
237,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
238,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
238,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
239,1,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
239,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
239,3,Tuberculosis,Tuberculous infections,Mycobacterial infectious disorders,Infec,N
240,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
240,2,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
240,3,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
241,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
242,1,Metastatic squamous cell carcinoma,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
242,2,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
243,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
244,1,Blast cell count increased,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
244,2,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
244,3,Hepatomegaly,Hepatobiliary signs and symptoms,Hepatic and hepatobiliary disorders,Hepat,N
244,4,Leukocytosis,Leukocytoses NEC,White blood cell disorders,Blood,N
244,5,Procedural haemorrhage,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
244,6,Subdiaphragmatic abscess,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
244,7,Thrombocytosis,Thrombocytoses,Platelet disorders,Blood,N
244,8,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
245,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
245,2,Skin cancer,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
246,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
247,1,Alanine aminotransferase abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
247,2,Delirium,Deliria,Deliria (incl confusion),Psych,N
247,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
247,4,Influenza,Influenza viral infections,Viral infectious disorders,Infec,N
247,5,Mental status changes,Mental disorders NEC,Psychiatric disorders NEC,Psych,N
247,6,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
247,7,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
247,8,Transaminases abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
248,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
248,2,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
249,1,Bladder cancer,Bladder neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
249,2,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
249,3,Metastases to lymph nodes,Metastases to specified sites,Metastases,Neopl,N
249,4,Neoplasm malignant,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
250,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
250,2,Peripheral vascular disorder,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
250,3,Retinal vascular disorder,Retinal bleeding and vascular disorders (excl retinopathy),"Retina, choroid and vitreous haemorrhages and vascular disorders",Eye,N
251,1,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
252,1,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
253,1,Langerhans' cell histiocytosis,Histiocytoses,Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
253,2,Vulvovaginal rash,Vulvovaginal signs and symptoms,Vulvovaginal disorders (excl infections and inflammations),Repro,N
254,1,Lip ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
255,1,Lip ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
256,1,Squamous cell carcinoma of skin,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
257,1,Squamous cell carcinoma,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
258,1,Adenovirus infection,Adenoviral infections,Viral infectious disorders,Infec,N
258,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
258,3,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
258,4,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
259,1,Adenovirus infection,Adenoviral infections,Viral infectious disorders,Infec,N
259,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
259,3,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
259,4,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
260,1,Colitis,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
261,1,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
261,2,Seminoma,Testicular neoplasms malignant,Reproductive neoplasms male malignant and unspecified,Neopl,N
262,1,Bursitis,Bursal disorders,Synovial and bursal disorders,Musc,N
262,2,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
262,3,Upper respiratory tract infection,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
263,1,Herpes zoster,Herpes viral infections,Viral infectious disorders,Infec,N
263,2,Staphylococcal infection,Staphylococcal infections,Bacterial infectious disorders,Infec,N
264,1,Disseminated tuberculosis,Tuberculous infections,Mycobacterial infectious disorders,Infec,Y
264,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
264,3,Granuloma,Inflammations,General system disorders NEC,Genrl,N
264,4,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
264,5,Septic shock,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
265,1,Squamous cell carcinoma,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
266,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
267,1,Squamous cell carcinoma,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
268,1,Photophobia,Ocular sensation disorders,Ocular sensory symptoms NEC,Eye,N
268,2,Scleritis,"Scleral infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
268,3,Uveitis,"Iris and uveal tract infections, irritations and inflammations","Ocular infections, irritations and inflammations",Eye,N
269,1,Cardiogenic shock,Heart failures NEC,Heart failures,Card,Y
270,1,Cardiac failure,Heart failures NEC,Heart failures,Card,Y
270,2,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
270,3,Endocarditis,Cardiac infections,Infections - pathogen unspecified,Infec,N
271,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
272,1,Drug level increased,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
273,1,Body temperature increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
274,1,Aspergillus infection,Aspergillus infections,Fungal infectious disorders,Infec,N
274,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
274,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
274,4,Full blood count abnormal,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
274,5,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
274,6,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
274,7,Onychomycosis,Fungal infections NEC,Fungal infectious disorders,Infec,N
274,8,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
275,1,Haemorrhage intracranial,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
276,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
276,2,Spinal cord neoplasm,Nervous system neoplasms unspecified malignancy NEC,Nervous system neoplasms malignant and unspecified NEC,Neopl,N
277,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
278,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
278,2,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
279,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
280,1,Squamous cell carcinoma of skin,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
281,1,Diffuse large B-cell lymphoma,Diffuse large B-cell lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,N
282,1,Panic attack,Panic attacks and disorders,Anxiety disorders and symptoms,Psych,N
283,1,Blood creatinine abnormal,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
283,2,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
283,3,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
283,4,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
284,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
285,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
285,2,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
286,1,Cholangitis,Bile duct infections and inflammations,Bile duct disorders,Hepat,N
286,2,Cholecystitis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
286,3,Cholelithiasis obstructive,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
286,4,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
286,5,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
286,6,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
287,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
287,2,Posterior reversible encephalopathy syndrome,Encephalopathies NEC,Encephalopathies,Nerv,N
288,1,Cognitive disorder,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
288,2,Disorientation,Confusion and disorientation,Deliria (incl confusion),Psych,N
288,3,Posterior reversible encephalopathy syndrome,Encephalopathies NEC,Encephalopathies,Nerv,N
288,4,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
289,1,Amnesia,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
289,2,Aphasia,Cortical dysfunction NEC,Neurological disorders NEC,Nerv,N
289,3,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
289,4,Disorientation,Confusion and disorientation,Deliria (incl confusion),Psych,N
289,5,Posterior reversible encephalopathy syndrome,Encephalopathies NEC,Encephalopathies,Nerv,N
289,6,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
289,7,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
290,1,Gout,Disorders of purine metabolism,Purine and pyrimidine metabolism disorders,Metab,N
291,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
292,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
293,1,Blood potassium increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
294,1,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
294,2,Metastasis,Metastases to unknown and unspecified sites,Metastases,Neopl,N
294,3,Neuroendocrine carcinoma of the skin,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
294,4,Skin induration,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
294,5,Skin mass,Skin and subcutaneous conditions NEC,Skin and subcutaneous tissue disorders NEC,Skin,N
295,1,High-grade B-cell lymphoma,B-cell lymphomas NEC,Lymphomas non-Hodgkin's B-cell,Neopl,N
295,2,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
296,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
296,2,Joint stiffness,Joint related signs and symptoms,Joint disorders,Musc,N
296,3,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
296,4,Mobility decreased,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
297,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
297,2,Postoperative wound infection,Infections NEC,Infections - pathogen unspecified,Infec,N
298,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
298,2,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
299,1,Emphysema,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
299,2,Lung neoplasm malignant,Respiratory tract and pleural neoplasms malignant cell type unspecified NEC,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,N
299,3,Pulmonary mass,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
299,4,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
299,5,Squamous cell carcinoma of lung,Non-small cell neoplasms malignant of the respiratory tract cell type specified,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,Y
300,1,Liposarcoma recurrent,Liposarcomas malignant,Soft tissue neoplasms malignant and unspecified,Neopl,N
300,2,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
300,3,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
301,1,Aicardi's syndrome,Neurological disorders congenital NEC,Neurological disorders congenital,Cong,N
301,2,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
302,1,Cardiac failure,Heart failures NEC,Heart failures,Card,N
302,2,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
302,3,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
302,4,Transformation to acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
303,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
303,2,Disseminated tuberculosis,Tuberculous infections,Mycobacterial infectious disorders,Infec,Y
303,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
303,4,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
304,1,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
304,2,Night sweats,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
304,3,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
305,1,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
305,2,Mouth haemorrhage,Oral soft tissue haemorrhages,Oral soft tissue conditions,Gastr,N
306,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
306,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
306,3,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
306,4,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
307,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
308,1,Hyponatraemia,Sodium imbalance,Electrolyte and fluid balance conditions,Metab,N
308,2,Inappropriate antidiuretic hormone secretion,Posterior pituitary disorders,Hypothalamus and pituitary gland disorders,Endo,N
308,3,Intestinal perforation,Intestinal ulcers and perforation NEC,Gastrointestinal ulceration and perforation,Gastr,N
309,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
309,2,Blood cholesterol increased,Cholesterol analyses,Lipid analyses,Inv,N
309,3,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
309,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
309,5,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
309,6,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
309,7,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
309,8,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
309,9,Rosacea,Rosaceas,Skin appendage conditions,Skin,N
309,10,Skin cancer,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
309,11,Skin graft failure,Transplantation complications,Procedural related injuries and complications NEC,Inj&P,N
309,12,Skin graft infection,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
309,13,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
310,1,Acute myeloid leukaemia recurrent,Leukaemias acute myeloid,Leukaemias,Neopl,N
310,2,Full blood count decreased,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
310,3,Influenza,Influenza viral infections,Viral infectious disorders,Infec,N
310,4,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
311,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
311,2,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
311,3,Scrotal swelling,Scrotal disorders NEC,Penile and scrotal disorders (excl infections and inflammations),Repro,N
312,1,Metastases to lung,Metastases to specified sites,Metastases,Neopl,N
312,2,Recurrent cancer,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
312,3,Skin cancer metastatic,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
313,1,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
313,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
313,3,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
314,1,Angioedema,Angioedemas,Angioedema and urticaria,Skin,N
314,2,Cardiac failure,Heart failures NEC,Heart failures,Card,N
314,3,Death,Death and sudden death,Fatal outcomes,Genrl,Y
314,4,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
315,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
316,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
316,2,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
317,1,Pulmonary tuberculosis,Tuberculous infections,Mycobacterial infectious disorders,Infec,N
318,1,Herpes zoster,Herpes viral infections,Viral infectious disorders,Infec,N
318,2,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
318,3,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
319,1,Basal cell carcinoma,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
319,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
319,3,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
319,4,Scab,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
319,5,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
319,6,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
320,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
320,2,Chronic graft versus host disease,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
320,3,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
321,1,Subdural haematoma,Cerebral injuries NEC,Injuries NEC,Inj&P,N
322,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
322,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
322,3,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
323,1,Metastatic squamous cell carcinoma,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
323,2,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
324,1,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
324,2,Skin squamous cell carcinoma metastatic,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
325,1,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
325,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
326,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
326,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
326,3,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
327,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
327,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
327,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
327,4,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
327,5,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
327,6,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
328,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
328,2,Leukocytosis,Leukocytoses NEC,White blood cell disorders,Blood,N
328,3,Skin squamous cell carcinoma metastatic,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
329,1,Fibrosis,Fibrosis NEC,Tissue disorders NEC,Genrl,N
329,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
329,3,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
330,1,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
330,2,Skin squamous cell carcinoma recurrent,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
331,1,Full blood count abnormal,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
331,2,Platelet count increased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
331,3,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
331,4,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
331,5,Skin squamous cell carcinoma recurrent,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
332,1,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
332,2,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
332,3,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
332,4,Haematuria,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
332,5,Iron deficiency,Iron deficiencies,Iron and trace metal metabolism disorders,Metab,N
332,6,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
333,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
333,2,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
333,3,White blood cell count abnormal,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
334,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
335,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
335,2,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
335,3,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
336,1,Encephalopathy,Encephalopathies NEC,Encephalopathies,Nerv,N
336,2,Memory impairment,Memory loss (excl dementia),Mental impairment disorders,Nerv,N
337,1,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
337,2,Pulmonary hypertension,Pulmonary hypertensions,Pulmonary vascular disorders,Resp,N
337,3,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
338,1,Coronavirus infection,Coronavirus infections,Viral infectious disorders,Infec,N
338,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
338,3,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
338,4,Head injury,Site specific injuries NEC,Injuries NEC,Inj&P,N
338,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
339,1,Blister,Bullous conditions,Epidermal and dermal conditions,Skin,N
340,1,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
341,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
341,2,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
341,3,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
341,4,Pneumocystis jirovecii pneumonia,Pneumocystis infections,Fungal infectious disorders,Infec,N
342,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
342,2,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
343,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,Y
344,1,Acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,N
344,2,Aplastic anaemia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
344,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
344,4,Neutropenic sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
345,1,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
346,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
346,2,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
346,3,Subdural haemorrhage,Cerebral injuries NEC,Injuries NEC,Inj&P,Y
346,4,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
347,1,Herpes zoster,Herpes viral infections,Viral infectious disorders,Infec,N
348,1,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
348,2,Skin cancer,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
349,1,Cardiac dysfunction,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
349,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
349,3,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
350,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
351,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
351,2,Complications of bone marrow transplant,Transplantation complications,Procedural related injuries and complications NEC,Inj&P,Y
352,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
352,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
352,3,Gastrointestinal haemorrhage,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
352,4,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
352,5,Night sweats,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
352,6,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
352,7,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
352,8,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
352,9,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
353,1,Abdominal discomfort,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
353,2,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
353,3,Haematocrit decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
353,4,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
353,5,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
354,1,Skin cancer,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,Y
355,1,Skin cancer,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
356,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
357,1,Bell's palsy,Facial cranial nerve disorders,Cranial nerve disorders (excl neoplasms),Nerv,N
357,2,Herpes simplex,Herpes viral infections,Viral infectious disorders,Infec,N
357,3,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
358,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
358,2,Pancreatitis acute,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,Y
358,3,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
358,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
359,1,Sarcomatoid carcinoma,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
360,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
360,2,Chronic obstructive pulmonary disease,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
360,3,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
361,1,Chimerism,Chromosomal abnormalities NEC,"Chromosomal abnormalities, gene alterations and gene variants",Cong,N
361,2,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
361,3,Epstein-Barr viraemia,Epstein-Barr viral infections,Viral infectious disorders,Infec,N
361,4,Epstein-Barr virus infection reactivation,Epstein-Barr viral infections,Viral infectious disorders,Infec,N
361,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
361,6,Parainfluenzae virus infection,Parainfluenzae viral infections,Viral infectious disorders,Infec,N
361,7,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
361,8,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
361,9,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
362,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
362,2,Haematocrit decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
363,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
364,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
364,2,Basophil count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
364,3,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
364,4,Haematotoxicity,Haematological disorders,Haematological disorders NEC,Blood,N
364,5,Headache,Headaches NEC,Headaches,Nerv,N
364,6,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
364,7,Intentional product use issue,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
364,8,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
364,9,Mood altered,Emotional and mood disturbances NEC,Mood disorders and disturbances NEC,Psych,N
364,10,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
364,11,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
364,12,Spleen disorder,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
364,13,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
365,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
365,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
365,3,Night sweats,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
365,4,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
365,5,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
366,1,Skin cancer metastatic,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
367,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
367,2,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
368,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
368,2,Night sweats,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
368,3,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
369,1,Basosquamous carcinoma of skin,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
370,1,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
370,2,Squamous cell carcinoma,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
371,1,Acne,Acnes,Skin appendage conditions,Skin,N
372,1,Bursitis,Bursal disorders,Synovial and bursal disorders,Musc,N
372,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
372,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
372,4,Myeloblast percentage increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
372,5,Thrombocytosis,Thrombocytoses,Platelet disorders,Blood,N
372,6,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
373,1,Metastatic squamous cell carcinoma,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
374,1,Quality of life decreased,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
375,1,Blast cell count increased,Haematological analyses NEC,Haematology investigations (incl blood groups),Inv,N
375,2,Death,Death and sudden death,Fatal outcomes,Genrl,Y
375,3,Haemoglobin abnormal,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
375,4,Herpes zoster,Herpes viral infections,Viral infectious disorders,Infec,N
375,5,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
375,6,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
375,7,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
375,8,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
375,9,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
375,10,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
375,11,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
376,1,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
376,2,Squamous cell carcinoma,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
377,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
377,2,Medication error,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
378,1,Meniere's disease,Inner ear disorders NEC,Inner ear and VIIIth cranial nerve disorders,Ear,N
378,2,Squamous cell carcinoma,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
379,1,Adenovirus infection,Adenoviral infections,Viral infectious disorders,Infec,N
379,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
379,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
379,4,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
379,5,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
380,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
380,2,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
381,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
381,2,Parkinson's disease,Parkinson's disease and parkinsonism,Movement disorders (incl parkinsonism),Nerv,N
381,3,Wrong technique in product usage process,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
382,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
382,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
382,3,Night sweats,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
382,4,Thrombocytosis,Thrombocytoses,Platelet disorders,Blood,N
382,5,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
383,1,Abdominal distension,"Flatulence, bloating and distension",Gastrointestinal signs and symptoms,Gastr,N
383,2,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
383,3,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
383,4,Basal cell carcinoma,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
383,5,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
383,6,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
383,7,Hyperhidrosis,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
383,8,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
383,9,Rash macular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
383,10,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
384,1,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
385,1,Malignant melanoma,Skin melanomas (excl ocular),Skin neoplasms malignant and unspecified,Neopl,N
385,2,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
386,1,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
387,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
387,2,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
387,3,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
388,1,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
388,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
389,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
389,2,Pallor,Site specific vascular disorders NEC,Vascular disorders NEC,Vasc,N
389,3,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
390,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
390,2,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
391,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
391,2,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
391,3,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
392,1,Loss of consciousness,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
392,2,Migraine,Migraine headaches,Headaches,Nerv,N
392,3,Visual impairment,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
393,1,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
393,2,Pulseless electrical activity,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,N
394,1,Cytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
395,1,Squamous cell carcinoma,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
396,1,Foot fracture,Limb fractures and dislocations,Bone and joint injuries,Inj&P,N
397,1,Squamous cell carcinoma,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
398,1,Cytomegalovirus infection,Cytomegaloviral infections,Viral infectious disorders,Infec,N
398,2,Immunosuppression,Immunodeficiency disorders NEC,Immunodeficiency syndromes,Immun,N
399,1,Cytomegalovirus infection reactivation,Cytomegaloviral infections,Viral infectious disorders,Infec,N
399,2,Full blood count decreased,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
399,3,Immunodeficiency,Immunodeficiency disorders NEC,Immunodeficiency syndromes,Immun,N
399,4,Immunosuppressant drug level increased,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
399,5,Nephrotic syndrome,Glomerulonephritis and nephrotic syndrome,Nephropathies,Renal,N
400,1,Blood phosphorus decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
400,2,Intestinal obstruction,Gastrointestinal stenosis and obstruction NEC,Gastrointestinal stenosis and obstruction,Gastr,N
400,3,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
400,4,Ovarian cancer metastatic,Ovarian neoplasms malignant (excl germ cell),Reproductive neoplasms female malignant and unspecified,Neopl,Y
401,1,Cutaneous vasculitis,Skin vasculitides,Skin vascular abnormalities,Skin,N
402,1,Brain abscess,Central nervous system and spinal infections,Infections - pathogen unspecified,Infec,N
403,1,Blood creatinine abnormal,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
403,2,Glomerular filtration rate decreased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
404,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
405,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
405,2,Graft versus host disease in skin,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
406,1,Inappropriate antidiuretic hormone secretion,Posterior pituitary disorders,Hypothalamus and pituitary gland disorders,Endo,N
407,1,Product supply issue,Product supply and availability issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
407,2,Stress,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
408,1,Product supply issue,Product supply and availability issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
408,2,Stress,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
409,1,Prostate cancer,Prostatic neoplasms malignant,Reproductive neoplasms male malignant and unspecified,Neopl,N
410,1,Drug level abnormal,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
410,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
410,3,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
410,4,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
410,5,Transient ischaemic attack,Transient cerebrovascular events,Central nervous system vascular disorders,Nerv,N
411,1,Neuroendocrine carcinoma of the skin,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
411,2,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
412,1,Herpes zoster,Herpes viral infections,Viral infectious disorders,Infec,N
413,1,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
413,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
414,1,Oral pain,Oral soft tissue signs and symptoms,Oral soft tissue conditions,Gastr,N
414,2,Skin cancer,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
415,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
415,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
415,3,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
415,4,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
415,5,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
416,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
416,2,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
417,1,Gangrene,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
418,1,Back injury,Site specific injuries NEC,Injuries NEC,Inj&P,N
419,1,Mycobacterium kansasii infection,Atypical mycobacterial infections,Mycobacterial infectious disorders,Infec,N
419,2,Osteomyelitis bacterial,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
420,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
421,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
422,1,Squamous cell carcinoma,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
423,1,Squamous cell carcinoma of skin,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
424,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
424,2,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
424,3,Basal cell carcinoma,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
424,4,Bone pain,Bone related signs and symptoms,Bone disorders (excl congenital and fractures),Musc,N
424,5,Decreased activity,Asthenic conditions,General system disorders NEC,Genrl,N
424,6,Depression,Depressive disorders,Depressed mood disorders and disturbances,Psych,N
424,7,Disturbance in attention,Mental impairment (excl dementia and memory loss),Mental impairment disorders,Nerv,N
424,8,Early satiety,Feelings and sensations NEC,General system disorders NEC,Genrl,N
424,9,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
424,10,Haemoglobin abnormal,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
424,11,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
424,12,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
424,13,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
424,14,Night sweats,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
424,15,Platelet count abnormal,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
424,16,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
424,17,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
424,18,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
424,19,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
424,20,White blood cell count abnormal,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
425,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
425,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
425,3,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
425,4,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
426,1,Abdominal pain upper,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
426,2,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
426,3,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
426,4,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
426,5,Night sweats,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
426,6,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
426,7,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
426,8,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
426,9,Pyelonephritis,Urinary tract infections,Infections - pathogen unspecified,Infec,N
426,10,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
426,11,Serum ferritin increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
426,12,Splenic infarction,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
426,13,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
426,14,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
426,15,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
426,16,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
427,1,Squamous cell carcinoma,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,Y
428,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
428,2,Leukaemia,Leukaemias NEC,Leukaemias,Neopl,N
429,1,Dyspnoea at rest,Breathing abnormalities,Respiratory disorders NEC,Resp,Y
430,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
430,2,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
431,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
432,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
433,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
433,2,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
433,3,Cardiac failure,Heart failures NEC,Heart failures,Card,Y
433,4,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
433,5,Drug withdrawal syndrome,Withdrawal and rebound effects,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
433,6,Eye ulcer,Ocular disorders NEC,Eye disorders NEC,Eye,N
433,7,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
433,8,Glomerular filtration rate decreased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
433,9,Headache,Headaches NEC,Headaches,Nerv,N
433,10,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
433,11,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
433,12,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
433,13,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
433,14,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
433,15,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
433,16,Withdrawal syndrome,Withdrawal and rebound effects,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
434,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
435,1,Epistaxis,Nasal disorders NEC,Upper respiratory tract disorders (excl infections),Resp,N
436,1,Blood potassium decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
437,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
438,1,Squamous cell carcinoma,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
439,1,Product supply issue,Product supply and availability issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
439,2,Vertigo,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
440,1,Actinic keratosis,Skin preneoplastic conditions NEC,Cornification and dystrophic skin disorders,Skin,N
440,2,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
440,3,Basal cell carcinoma,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
440,4,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
440,5,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
440,6,Salivary gland neoplasm,Salivary gland neoplasms unspecified malignancy,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
440,7,Skin papilloma,Skin neoplasms benign,Cutaneous neoplasms benign,Neopl,N
440,8,Squamous cell carcinoma,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
441,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
441,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
441,3,Full blood count decreased,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
441,4,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
441,5,Kidney infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
442,1,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
443,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
443,2,Monoplegia,Paralysis and paresis (excl cranial nerve),Movement disorders (incl parkinsonism),Nerv,N
444,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
444,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
445,1,Leukocytosis,Leukocytoses NEC,White blood cell disorders,Blood,N
446,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
446,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
446,3,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
446,4,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
447,1,Metastatic malignant melanoma,Skin melanomas (excl ocular),Skin neoplasms malignant and unspecified,Neopl,N
447,2,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
448,1,Affective disorder,Mood disorders NEC,Mood disorders and disturbances NEC,Psych,N
448,2,Deafness,Hearing losses,Hearing disorders,Ear,N
448,3,Mental disorder,Mental disorders NEC,Psychiatric disorders NEC,Psych,N
448,4,Tinnitus,Inner ear signs and symptoms,Inner ear and VIIIth cranial nerve disorders,Ear,N
449,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
450,1,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
451,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
451,2,Herpes zoster,Herpes viral infections,Viral infectious disorders,Infec,N
452,1,Squamous cell carcinoma,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
453,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
454,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
455,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
456,1,Headache,Headaches NEC,Headaches,Nerv,N
457,1,Platelet count increased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
458,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
458,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
458,3,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
458,4,Product prescribing error,Product prescribing errors and issues,Medication errors and other product use errors and issues,Inj&P,N
458,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
459,1,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
459,2,Squamous cell carcinoma of skin,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
460,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
460,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
461,1,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
462,1,Rebound effect,Withdrawal and rebound effects,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
463,1,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
464,1,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
464,2,Skin cancer,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
464,3,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
465,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
465,2,Headache,Headaches NEC,Headaches,Nerv,N
466,1,Hepatic steatosis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
466,2,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
467,1,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
467,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
468,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
469,1,Chronic myeloid leukaemia,Leukaemias chronic myeloid,Leukaemias,Neopl,N
469,2,Second primary malignancy,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
469,3,White blood cell count increased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
470,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
471,1,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
471,2,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
471,3,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
471,4,Product use in unapproved therapeutic environment,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
472,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
472,2,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
472,3,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
473,1,Haematocrit decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
473,2,Platelet count increased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
474,1,COVID-19,Coronavirus infections,Viral infectious disorders,Infec,N
474,2,Product dose omission issue,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
475,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
475,2,Hallucination,Hallucinations (excl sleep-related),Disturbances in thinking and perception,Psych,N
475,3,JC virus infection,Polyomavirus infections,Viral infectious disorders,Infec,Y
475,4,Progressive multifocal leukoencephalopathy,Polyomavirus infections,Viral infectious disorders,Infec,N
475,5,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
476,1,Platelet count increased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
477,1,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
477,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
477,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
477,4,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
477,5,Urine analysis abnormal,Urinalysis NEC,Renal and urinary tract investigations and urinalyses,Inv,N
477,6,Viral infection,Viral infections NEC,Viral infectious disorders,Infec,N
478,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
479,1,Platelet count increased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
480,1,Diverticulitis,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
481,1,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
481,2,Suicide threat,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
482,1,Aplastic anaemia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
483,1,Neuroendocrine carcinoma of the skin,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
484,1,Neuroendocrine carcinoma of the skin,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
485,1,Full blood count decreased,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
486,1,Progressive multifocal leukoencephalopathy,Polyomavirus infections,Viral infectious disorders,Infec,N
487,1,Full blood count decreased,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
487,2,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
488,1,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
489,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
490,1,Progressive multifocal leukoencephalopathy,Polyomavirus infections,Viral infectious disorders,Infec,N
491,1,Haematocrit decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
491,2,Iron deficiency,Iron deficiencies,Iron and trace metal metabolism disorders,Metab,N
491,3,Platelet count increased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
492,1,Back pain,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
492,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
492,3,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
492,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
493,1,Constipation,Gastrointestinal atonic and hypomotility disorders NEC,Gastrointestinal motility and defaecation conditions,Gastr,N
494,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
494,2,Haematocrit decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
494,3,Iron deficiency,Iron deficiencies,Iron and trace metal metabolism disorders,Metab,N
494,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
494,5,Platelet count increased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
495,1,Death,Death and sudden death,Fatal outcomes,Genrl,N
496,1,Skin cancer,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
497,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
497,2,Platelet count decreased,Platelet analyses,Haematology investigations (incl blood groups),Inv,N
498,1,Skin cancer,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
499,1,Herpes zoster,Herpes viral infections,Viral infectious disorders,Infec,N
500,1,Skin cancer,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
501,1,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
501,2,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
501,3,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
502,1,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
503,1,Herpes zoster,Herpes viral infections,Viral infectious disorders,Infec,N
504,1,White blood cell disorder,White blood cell abnormal findings NEC,White blood cell disorders,Blood,N
505,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
505,2,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
505,3,Aphasia,Cortical dysfunction NEC,Neurological disorders NEC,Nerv,N
505,4,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
505,5,Ataxia,Coordination and balance disturbances,Neurological disorders NEC,Nerv,N
505,6,Brain stem infarction,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
505,7,Central nervous system immune reconstitution inflammatory response,Central nervous system inflammatory disorders NEC,Central nervous system infections and inflammations,Nerv,N
505,8,Dysarthria,Speech and language abnormalities,Neurological disorders NEC,Nerv,N
505,9,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
505,10,Iron overload,Iron excess,Iron and trace metal metabolism disorders,Metab,N
505,11,JC virus infection,Polyomavirus infections,Viral infectious disorders,Infec,N
505,12,Mycobacterium avium complex infection,Atypical mycobacterial infections,Mycobacterial infectious disorders,Infec,N
505,13,Overchelation,Mineral related disorders NEC,Iron and trace metal metabolism disorders,Metab,N
505,14,Progressive multifocal leukoencephalopathy,Polyomavirus infections,Viral infectious disorders,Infec,Y
506,1,Fibrosis,Fibrosis NEC,Tissue disorders NEC,Genrl,N
506,2,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
506,3,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
506,4,Splenic thrombosis,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
507,1,Lymphocytic leukaemia,Leukaemias lymphocytic NEC,Leukaemias,Neopl,N
508,1,Full blood count abnormal,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
508,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
508,3,Thrombocytosis,Thrombocytoses,Platelet disorders,Blood,N
508,4,Ulcer,Ulcers NEC,Tissue disorders NEC,Genrl,N
509,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
510,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
510,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
510,3,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,Y
510,4,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
510,5,Quality of life decreased,Investigations NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
510,6,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
510,7,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
511,1,Scrotal cellulitis,Male reproductive tract infections,Infections - pathogen unspecified,Infec,N
512,1,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
512,2,Pain in extremity,Musculoskeletal and connective tissue pain and discomfort,Musculoskeletal and connective tissue disorders NEC,Musc,N
513,1,Asthenia,Asthenic conditions,General system disorders NEC,Genrl,N
513,2,Dizziness postural,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
513,3,Headache,Headaches NEC,Headaches,Nerv,N
513,4,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
513,5,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
513,6,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
513,7,Transformation to acute myeloid leukaemia,Leukaemias acute myeloid,Leukaemias,Neopl,Y
514,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
514,2,Full blood count abnormal,Blood counts NEC,Haematology investigations (incl blood groups),Inv,N
514,3,Malignant neoplasm progression,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
514,4,Myelofibrosis,Myeloproliferative disorders (excl leukaemias),Haematopoietic neoplasms (excl leukaemias and lymphomas),Neopl,N
514,5,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
515,1,Streptococcal infection,Streptococcal infections,Bacterial infectious disorders,Infec,N
516,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
517,1,Skin cancer,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
518,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
518,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
518,3,Night sweats,Apocrine and eccrine gland disorders,Skin appendage conditions,Skin,N
518,4,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
518,5,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
519,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
519,2,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
519,3,Budd-Chiari syndrome,Hepatic vascular disorders,Hepatic and hepatobiliary disorders,Hepat,N
519,4,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
519,5,Headache,Headaches NEC,Headaches,Nerv,N
519,6,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
519,7,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
519,8,Weight increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
520,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
521,1,Skin cancer,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
